SHIFT Newsroom · GLOBAL
Adolescent obesity medicines: a review, with longer-term gaps
This review discusses existing and forthcoming pharmacotherapies for adolescent obesity, including medicine-specific evidence and safety considerations. It is not a new efficacy trial. Adolescent licensing and specialist-care requirements need current UK sources.
What the source says
This review discusses existing and forthcoming pharmacotherapies for adolescent obesity, including medicine-specific evidence and safety considerations. It is not a new efficacy trial. Adolescent licensing and specialist-care requirements need current UK sources.
Evidence and limits
The review considers trials and meta-analyses involving adolescents and discusses medicines including semaglutide. It also describes costs, access inequalities and longer-term evidence gaps. The earlier claims that medicine and safety details were absent were too broad.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
This is a specialist adolescent evidence review. It does not change an adult service’s eligibility or create a treatment offer for children.
Known facts
- This review discusses existing and forthcoming pharmacotherapies for adolescent obesity, including medicine-specific evidence and safety considerations.